• Skip to primary navigation
  • Skip to main content
  • Skip to footer
MotherToBaby

MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

Hide Search
Shopping Cart
Show SearchSearch
866.626.6847
  • About
    • Our Work
    • Our Team
    • Our Partners
  • Exposures
    • Pregnancy and Breastfeeding Exposures
    • Fact Sheets
    • Baby Blogs
    • Podcasts
  • Studies
    • Ongoing Studies
    • What’s Involved?
    • Join Now
    • Health Providers
    • Pharma Industry
    • Publications
  • Health Professionals
    • Patient Education and Provider Resources
    • Refer a Patient
    • Request Materials
    • Meetings
    • FAQs
    • OTIS Membership
  • Media
    • Media Requests
    • Press Releases
    • eNews Sign Up
  • In Your Area
  • OTIS
    • About OTIS
    • OTIS Membership
    • Annual Meeting
    • Member Log-In
    • Donate
  • Contact
  • Show SearchSearch

Tofacitinib (Xeljanz®, Xeljanz XR®)

October 1, 2021

Selected References:

  • Clowse, M, et al. 2016. Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.Drug Saf. 39:755-762,
  • Fernández-Sánchez M, et al. 2021. Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report. Birth Defects Res. 113(17):1275-1279.
  • Mahadevan, U., et al 2018. Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databasesfor Ulcerative Colitis. Inflammatory Bowel Diseases, 24(12), 2494–2500.doi: 10.1093/ibd/izy160
  • Mahadevan U, et al. 2019. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology, 156(5), 1508-1524.
  • Merren A, et al. 2015. Pregnancy Outcomes in the tofacitinib RA study database through April 2014.Abstract doi 10.1136/annrheumdis-2015-eular.3547.
  • Picardo S, Seow CH. 2019. A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy. Drugs;79(10):1053-1063.

Footer

           

Hot Links

  • Home
  • Exposures
  • Fact Sheets
  • Baby Blogs
  • Podcasts
  • Pregnancy Studies
  • Join a Study Now
  • Healthcare Professionals
  • Refer a Patient
  • Request Materials
  • News
  • Donate
  • Ask An Expert

Current Studies

  • Ankylosing Spondylitis
  • Asthma
  • Coronavirus (COVID-19)
  • Crohn’s Disease
  • Eczema (Moderate-to-Severe)/Atopic Dermatitis
  • Juvenile Idiopathic Arthritis
  • Multiple Sclerosis
  • Pertussis/Tdap vaccine (“Whooping Cough” vaccine)
  • Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Ulcerative Colitis

Contact

Exposure Information Service
866.626.6847

Pregnancy Studies
877.311.8972

Media Inquiries
619.368.3259
nchavez@mothertobaby.org

MotherToBaby, a service of the Organization of Teratology Information Specialists
OTIS Logo

Copyright © 2023 The Organization of Teratology Information Specialists

  • Accessibility
  • Privacy
  • Terms
  • Site Map
^